• We determined whether the response of thyrotropin (TSH) to thyrotropin-releasing hormone could predict the outcome of treatment with antidepressant and neuroleptic drugs. We studied 114 female patients diagnosed as having major and minor depressive, manic, schizoaffective, and schizophrenic disorders. A blunted TSH response (<5 μU/mL [<5 mU/L]) at admission was associated with recovery after nine weeks of inpatient treatment using clomipramine hydrochloride for depression and haloperidol for psychosis. A blunted TSH response at discharge was associated with early relapse in depressives receiving clomipramine maintenance therapy. Our findings support the notion that the thyrotropin-releasing hormone test is a "state" marker that may be of use in predicting the outcome of treatment with antidepressant and neuroleptic drugs.
Langer G, Koinig G, Hatzinger R, et al. Response of Thyrotropin to Thyrotropin-Releasing Hormone as Predictor of Treatment Outcome: Prediction of Recovery and Relapse in Treatment With Antidepressants and Neuroleptics. Arch Gen Psychiatry. 1986;43(9):861–868. doi:10.1001/archpsyc.1986.01800090047007
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: